Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRA vs CODX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMRA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–5 Matrix Metrics)

BMRA Overall Winner 6-Pillar Tally: BMRA 3 – 2 CODX (1 Tie) Matrix Metrics: BMRA 4 – 5 CODX

As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over Co-Diagnostics, Inc. (CODX) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas CODX carries 51.6/100 (HOLD) at $0.23 (15.4x Forward P/E, -3415.8% operating margin).

  • Composite vs. Pillar Nuance: While CODX currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. BMRA 44.5/100 HOLD), BMRA captures the overall institutional head-to-head verdict (4–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-125.2% vs. -3415.8% operating margin) and revenue trajectory (-8.3% vs. +94.6% YoY).
  • Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile CODX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRA vs CODX
BMRA NASDAQ Head-to-Head Winner
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96
CODX NASDAQ
Co-Diagnostics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.23
-11.68% 1D
Market Cap $2.3M
TTM Revenue $858,888
Forward P/E 15.4x
Beta / 30D Vol 2.93β · 148% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 55.0 Fund 54.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.1%), weak momentum, RSI 22
RSI-14: 21.7 · SMA20: $0.39 · SMA50: $0.78

6-Pillar Scorecard Institutional Category Breakdown (BMRA 3 – 2 CODX)

Columns: Metric · BMRA · CODX
1. Valuation Multiples CODX
Forward P/E N/M 15.4x
Trailing P/E N/M 15.4x
PEG Ratio N/M N/M
EV / Revenue 1.1x N/M
2. Growth & Scale CODX
Revenue Growth (YoY) -8.3% +94.6%
Earnings Growth (YoY) +0.0% +30.8%
TTM Revenue (USD) $4.3M $858,888
Market Cap $6.0M $2.3M
3. Profitability & Quality BMRA
Gross Margin 0.9% 20.3%
Operating Margin -125.2% -3415.8%
Net Profit Margin -115.5% 0.0%
Return on Equity (ROE) -113.8% -192.8%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$3.2M -$28M EBITDA
Cash Flow Margin -73.5% N/A
Net Cash / Leverage $1.1M Net Cash $6.2M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BMRA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 270.2% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRA (4) vs CODX (5)
Institutional Metric BMRA CODX Criterion Row Edge
Market Capitalization
Scale
$6.0M $2.3M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 15.4x Lower Multiple CODX
Forward P/E Ratio
Valuation
N/M 15.4x Lower Multiple CODX
Revenue Growth (YoY)
Growth
-8.3% +94.6% Higher Growth CODX
Operating Margin (TTM)
Profitability
-125.2% -3415.8% Higher Margin BMRA
Net Profit Margin
Profitability
-115.5% 0.0% Higher Margin CODX
Return on Equity (ROE)
Capital Efficiency
-113.8% -192.8% Higher ROE BMRA
52-Week Range Position
Momentum
5% ($1–$3) 0% ($0–$14) Stronger Trend BMRA
Beta / 30D Volatility
Risk Regime
0.67β · 62% Vol 2.93β · 148% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 51.6 / 100 (HOLD) Higher Composite CODX
Trailing 12M Revenue (USD)
Operating Scale
$4.3M $858,888 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.9% 20.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.2M ($1.1M Net Cash) -$28M EBITDA ($6.2M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BMRA +38.59 pp
BMRA: -26.49% · CODX: -65.08%
3M Horizon BMRA +66.87 pp
BMRA: -15.0% · CODX: -81.87%
6M Horizon BMRA +43.77 pp
BMRA: -39.56% · CODX: -83.33%
1Y Horizon CODX +7.0 pp
BMRA: -45.6% · CODX: -38.6%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BMRA Revenue CODX Revenue BMRA Op. Margin CODX Op. Margin Margin Leader
FY2019 $10M $0M -46.4% -2741.6% BMRA
FY2020 $10M $70M -41.0% 55.9% CODX
FY2021 $10M $100M -104.2% 47.1% CODX
FY2022 $20M $30M -24.0% -78.8% BMRA
FY2023 $10M $10M -135.3% -626.9% BMRA
FY2024 $10M $0M -117.6% -1023.7% BMRA
FY2025 $10M $0M -96.7% -8058.8% BMRA
FY2026 $0M N/A -119.5% N/A BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CODX BREAKDOWN
173d in phase · OBV DISTRIBUTION
Current IV 270.2%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CODX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CODX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $2.3M market capitalization and -3415.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BMRA vs CODX Key Questions & Quantitative Answers

As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over Co-Diagnostics, Inc. (CODX) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas CODX carries 51.6/100 (HOLD) at $0.23 (15.4x Forward P/E, -3415.8% operating margin). Composite vs. Pillar Nuance: While CODX currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. BMRA 44.5/100 HOLD), BMRA captures the overall institutional head-to-head verdict (4–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-125.2% vs. -3415.8% operating margin) and revenue trajectory (-8.3% vs. +94.6% YoY). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile CODX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CODX leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with CODX at +94.6% YoY revenue growth and +30.8% YoY earnings growth on $858,888 TTM revenue (20.3% gross margin, -3415.8% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while CODX shifted -85.7%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CODX.

CODX screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas CODX trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus CODX (-192.8% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, CODX carries 270.2% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.93β · 148% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.